0001209191-20-043886.txt : 20200728
0001209191-20-043886.hdr.sgml : 20200728
20200728183055
ACCESSION NUMBER: 0001209191-20-043886
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200728
FILED AS OF DATE: 20200728
DATE AS OF CHANGE: 20200728
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Sonsini Peter W.
CENTRAL INDEX KEY: 0001559807
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39397
FILM NUMBER: 201055117
MAIL ADDRESS:
STREET 1: 2855 SAND HILL ROAD
CITY: MENLO PARK
STATE: CA
ZIP: 94025
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Inozyme Pharma, Inc.
CENTRAL INDEX KEY: 0001693011
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 475129768
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 321 SUMMER STREET
STREET 2: SUITE 400
CITY: BOSTON
STATE: MA
ZIP: 02210
BUSINESS PHONE: 857-330-4340
MAIL ADDRESS:
STREET 1: 321 SUMMER STREET
STREET 2: SUITE 400
CITY: BOSTON
STATE: MA
ZIP: 02210
FORMER COMPANY:
FORMER CONFORMED NAME: Inozyme Pharma, LLC
DATE OF NAME CHANGE: 20161222
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-07-28
0
0001693011
Inozyme Pharma, Inc.
INZY
0001559807
Sonsini Peter W.
2855 SAND HILL ROAD
MENLO PARK
CA
94025
0
0
1
0
Common Stock
2020-07-28
4
C
0
2000533
A
2000533
I
See Note 2
Common Stock
2020-07-28
4
C
0
187156
A
2187689
I
See Note 2
Common Stock
2020-07-28
4
P
0
250000
16.00
A
2437689
I
See Note 2
Series A Preferred Stock
2020-07-25
4
C
0
2000533
0.00
D
Common Stock
2000533
0
I
See Note 2
Series A-2 Preferred Stock
2020-07-25
4
C
0
187156
0.00
D
Common Stock
187156
0
I
See Note 2
On July 28, 2020, the Series A Preferred Stock converted into Common Stock on a 7.473-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.
The Reporting Person is a manager of NEA 15 GP, LLC, which is the sole general partner of NEA Partners 15, L.P. ("NEA Partners 15"). NEA Partners 15 is the sole general partner of New Enterprise Associates 15, L.P. ("NEA 15"), which is the direct beneficial owner of the shares. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the shares held by NEA 15 in which the Reporting Person has no pecuniary interest.
On July 28, 2020, the Series A-2 Preferred Stock converted into Common Stock on a 7.473-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.
/s/ Sasha Keough, attorney-in-fact
2020-07-28